Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

JAK-STAT inhibitors reverse MS-like disease in mice

A new class of drugs completing clinical trials soon for rheumatoid arthritis should be examined as a treatment for multiple sclerosis, according to the authors of a University of Alabama at Birmingham study published today in the Proceedings of the National Academy of Sciences.

13 Mar 2012

Researchers unlock mystery of how an inflammatory molecule is produced in the body

Cedars-Sinai researchers have unlocked the mystery of how an inflammatory molecule is produced in the body, a discovery they say could lead to advances in the treatment of rheumatoid arthritis, Type 2 diabetes and numerous other chronic diseases that affect tens of millions of people.

12 Mar 2012

Antares Pharma fourth quarter revenues increase 65% to $5.4 million

Antares Pharma, Inc. today reported financial and operating results for the fourth quarter and full year ended December 31, 2011 and outlined key objectives and milestones for 2012.

12 Mar 2012

TSRI, OPKO Health to develop and commercialize SR 3306 for Parkinson's

OPKO Health, Inc. and The Scripps Research Institute today announced a global agreement for the development and commercialization of SR 3306, a novel compound discovered by scientists from the Florida campus of The Scripps Research Institute that blocks the destruction of brains cells in animal models of Parkinson's disease.

12 Mar 2012

New inexpensive medical sensor may simplify diagnosis of diseases

An inexpensive new medical sensor has the potential to simplify the diagnosis of diseases ranging from life-threatening immune deficiencies to the common cold, according to its inventors at the Stanford University School of Medicine.

8 Mar 2012

Zalicus fourth quarter revenue decreases to $8.2 million

Zalicus Inc. today reported financial results for the fourth quarter and year ended December 31, 2011.

8 Mar 2012

New FDA approved drug to treat infants with respiratory distress syndrome

Scientific advances at The Scripps Research Institute have led to a new drug Surfaxin (lucinactant), approved today by the U.S. Food and Drug Administration (FDA) to treat infant respiratory distress syndrome.

7 Mar 2012

A novel approach to treating rheumatoid arthritis

Rheumatoid arthritis is a crippling disease and is caused when the body's own immune system attacks the joints and leads to chronic pain and inflammation. A team from Newcastle University funded by Arthritis Research UK have discovered an approach which could effectively prevents white blood cells from reaching the joints and causing more damage.

7 Mar 2012

Pharmspective releases first knowledge management application: ClearView

Pharmspective, LLC today announced the release of its first knowledge management application - ClearView - specifically developed to analyze provisions in the health care reform law and their impact on key pharma customer decision makers who influence product adoption.

7 Mar 2012

Anthera continues Phase 2b PEARL-SC clinical study in SLE patients

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases including cardiovascular and autoimmune disorders, today announced the continuation of the Phase 2b PEARL-SC clinical study following an interim analysis of all safety and efficacy data.

5 Mar 2012

AARDA hopes to educate public on autoimmune diseases during March

March is National Autoimmune Diseases Awareness Month, and the American Autoimmune Related Diseases Association (AARDA) is working to educate the public on risk factors, prevalence, and the severe lack of awareness surrounding autoimmune diseases.

3 Mar 2012

New ACR classification criteria for polymyalgia rheumatica

The American College of Rheumatology has released the first classification criteria for polymyalgia rheumatica - aimed at helping physicians identify patients with this condition, which occurs in persons aged 50 years or older who have recent onset of pain in the shoulders, neck and hips along with other inflammatory symptoms not explained by an alternate diagnosis.

2 Mar 2012

Preliminary results from Genentech's ACTEMRA monotherapy study on RA

Genentech, a member of the Roche Group, today announced that preliminary results from the ADACTA (ADalimumab ACTemrA) study showed that patients who received ACTEMRA (tocilizumab) as monotherapy achieved a significantly greater reduction in disease activity after 24 weeks than those given adalimumab monotherapy.

2 Mar 2012

Akeso Medical Imaging starts clinical study for proof of concept of imaging device for rheumatoid arthritis disease activity monitoring and control

Akeso Medical Imaging BV, announces today the start of a clinical study with their novel imaging device for assessment of joint inflammation in patient with rheumatoid arthritis (RA). In this proof of concept study, Akeso’s imaging device will be compared to other methods to assess disease status, such as the DAS-28 score, Ultrasound and in some cases MRI. The study will be performed at the University Medical Center Utrecht (UMC Utrecht) in cooperation with Regional Rheumatology Centre Eindhoven (RRC). Seventy subjects will be included; sixty RA patients with varying degrees of inflammation of the joints of hands and wrists at the time of examination and a control group of ten subjects.

1 Mar 2012

Cyclotides discovery may open up new possibilities for immune suppression

A team of researchers at the MedUni Vienna, together with scientists from the University Hospital of Freiburg, has decoded a mechanism in cyclic plant peptides, known as cyclotides, from the family of coffee plants (Rubiaceae) that could open up new possibilities for immune suppression.

1 Mar 2012

TUT creates first biodegradable joint implant for arthritic patients

Tampere University of Technology (TUT), Finland, has been the first in the world to develop biodegradable joint implant, RegJoint-. The implant is used in the treatment of osteoarthritis and rheumatoid arthritis.

29 Feb 2012

NHS approves new rheumatoid arthritis drug RoActemra

RoActemra, which is the first innovation in the field for ten years, is being recommended for patients who have failed on standard treatments. It is the first time RoActemra has been approved for NHS patients in England and Wales with moderate to severe rheumatoid arthritis who are at an early stage in the disease. The drug has been available for early use in Scotland for two years.

23 Feb 2012